Geng, Degui | University of Maryland School of Medicine
WEBDegui Geng, PhD. Academic Title: Assistant Professor. Primary Appointment: Pharmacology. Download CV.
Degui GENG | University of Maryland, Baltimore, Maryland
WEBDegui GENG | Cited by 767 | of University of Maryland, Baltimore, Maryland (UMB) | Read 27 publications | Contact Degui GENG.
Geng Degui - Postdoc Fellow - University of Maryland School
WEBPostdoc Fellow at University of Maryland School of Medicine · Experience: University of Maryland School of Medicine · Location: Baltimore · 1 connection on LinkedIn.
- Title: Postdoc Fellow at University …
- Location: University of Maryland School of Medicine
Division Faculty | University of Maryland School of Medicine - IHV
WEBInstitute of Human Virology. The Charles Gordon Smith Professor for HIV Research. University of Maryland School of Medicine. Degui Geng, PhD: IHV, Assistant Professor, Pharmacology. Yan Liu, PhD: IHV, Assistant Professor, Surgery. Xu Wang, PhD: IHV, Research Associate, Pharmacology.
Induction of IRAK-M in melanoma induces caspase-3 dependent
WEBJun 12, 2020 · Although recent years have seen advances using targeted and immunotherapies, most patients remain at high risk for tumor recurrence. Here we show that IRAK-M, a negative regulator of MyD88 signaling, is deficient or low in melanoma and expression levels correlate with patient survival.
Amplifying TLR-MyD88 signals within tumor-specific T cells …
WEBOct 1, 2010 · Degui Geng 1 , Liqin Zheng, Ratika Srivastava, Cruz Velasco-Gonzalez, Adam Riker, Svetomir N Markovic, Eduardo Davila Affiliation 1 University of Maryland Greenebaum Cancer Center and Department of Otorhinolaryngology, Baltimore, Maryland 21201-1559, USA.
When Toll-like receptor and T-cell receptor signals collide: a ...
WEBNov 4, 2010 · Degui Geng 1 , Liqin Zheng, Ratika Srivastava, Nicole Asprodites, Cruz Velasco-Gonzalez, Eduardo Davila Affiliation 1 University of Maryland Greenebaum Cancer Center, 655 W. Baltimore Street, Baltimore, MD 21201, USA.
TLR5 Ligand–Secreting T Cells Reshape the Tumor …
WEBMay 13, 2015 · Abstract. The tumor microenvironment counters antitumor T-cell responses, in part, by blunting their activation and infiltration. Ligands that engage Toll-like receptors (TLR) on T cells and antigen-presenting cells can act as potent immune adjuvants.
Augmentation of Therapeutic Responses in Melanoma by …
WEBNov 29, 2012 · Treatment failure is largely attributed to melanoma's resistance to all existing forms of cancer therapies. Recent reports indicate that Toll-like receptors (TLR) signaling within nonimmune cells, including several types of human cancers, can contribute to cancer progression (4–7).
When Toll-like receptor and T-cell receptor signals collide: a ...
WEBNov 4, 2010 · Degui Geng, Liqin Zheng, Ratika Srivastava, Nicole Asprodites, Cruz Velasco-Gonzalez, Eduardo Davila; When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 2010; 116 (18): 3494–3504. doi: https://doi.org/10.1182/blood-2010-02 …
Skip to content